Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib and Pembrolizumab in Metastatic Colorectal Cancer (LEAP-017)
NCT04776148Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2021
- Primary completion
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of lenvatinib, pembrolizumab in colorectal cancer (metastatic) (mCRC), sponsored by Merck & Co.. Started Mar 2021; status: completed.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT04776148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04776148.